Joanna Barbara Braksator

Dr. Joanna Barbara Braksator

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
HSHubert Paweł Szyller
Hubert Paweł Szyller
KAKatarzyna Antosz
Katarzyna Antosz
JKJoanna Koga-Batko
Joanna Koga-Batko
AMAgata Mytych
Agata Mytych
MDMarta Dziedziak
Marta Dziedziak
TPTomasz Pytrus
Tomasz Pytrus
The composition of human breast milk is an ideal combination of substances necessary for the healthy development of an infant’s body while protecting from pathogens and the balanced development of the microbiota. Its composition is dynamic and changes with the age of the child, meeting their current needs. The study provides a thorough overview of human milk components, such as immunological components, growth factors, hormones, carbohydrates, lipids, minerals, and vitamins. Authors focus on capturing the most important aspects of the effects of these substances on a newborn’s body, while also looking for specific connections and describing the effects on given systems. Supplementation and the use of ingredients are also discussed. The purpose of this paper is to present the current state of knowledge about the bioactive components of human milk and their impact on the growth, development, and health of the young child.

Verified
Journal Article
Open access
PDF file
GAGabriela Augustynowicz
Gabriela Augustynowicz
MLMaria Lasocka
Maria Lasocka
HSHubert Paweł Szyller
Hubert Paweł Szyller
MDMarta Dziedziak
Marta Dziedziak
AMAgata Mytych
Agata Mytych
TPTomasz Pytrus
Tomasz Pytrus
The gut microbiota, dominated by bacteria from the Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria phyla, plays an essential role in fermenting indigestible carbohydrates, regulating metabolism, synthesizing vitamins, and maintaining immune functions and intestinal barrier integrity. Dysbiosis is associated with obesity development. Shifts in the ratio of Firmicutes to Bacteroidetes, particularly an increase in Firmicutes, may promote enhanced energy storage, appetite dysregulation, and increased inflammatory processes linked to insulin resistance and other metabolic disorders. The purpose of this literature review is to summarize the current state of knowledge on the relationship between the development and treatment of obesity and overweight and the gut microbiota. Current evidence suggests that probiotics, prebiotics, synbiotics, and fecal microbiota transplantation (FMT) can influence gut microbiota composition and metabolic parameters, including body weight and BMI. The most promising effects are observed with probiotic supplementation, particularly when combined with prebiotics, although efficacy depends on strain type, dose, and duration. Despite encouraging preclinical findings, FMT has shown limited and inconsistent results in human studies. Diet and physical activity are key modulators of the gut microbiota. Fiber, plant proteins, and omega-3 fatty acids support beneficial bacteria, while diets low in fiber and high in saturated fats promote dysbiosis. Aerobic exercise increases microbial diversity and supports growth of favorable bacterial strains. While microbiota changes do not always lead to immediate weight loss, modulating gut microbiota represents an important aspect of obesity prevention and treatment strategies. Further research is necessary to better understand the mechanisms and therapeutic potential of these interventions.

29 August 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
MDMarta Dziedziak
Marta Dziedziak
AMAgata Mytych
Agata Mytych
HSHubert Paweł Szyller
Hubert Paweł Szyller
MLMaria Lasocka
Maria Lasocka
GAGabriela Augustynowicz
Gabriela Augustynowicz
TPTomasz Pytrus
Tomasz Pytrus
Recent studies increasingly highlight the complex interaction between gut microbiota and mental health, drawing attention to the role of the microbiota–gut–brain axis (MGBA) in the pathophysiology of mental and neurodevelopmental disorders. Changes in the composition of the gut microbiota—dysbiosis—are associated with conditions such as depression, schizophrenia, bipolar disorder (BD), autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), and neurodegenerative diseases such as Parkinson’s and Alzheimer’s. These microbial imbalances can affect brain function through a variety of mechanisms, including activation of the immune system, alteration of intestinal permeability, modulation of the digestive and central nervous systems, and changes in the production of neuroactive metabolites such as short-chain fatty acids, serotonin, and tryptophan derivatives. The aim of this paper is to review the current state of knowledge on therapeutic strategies targeting the gut microbiome—including probiotics, prebiotics, synbiotics, personalized dietary interventions, and fecal microbiota transplantation (FMT)—which are becoming promising adjuncts or alternatives to conventional psychopharmacology, offering a forward-looking and individualized approach to mental health treatment. Understanding the bidirectional and multifactorial nature of MGBA may pave the way for new, integrative treatment paradigms in psychiatry and neurology, requiring further research and exploration of their scope of application.

25 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Katarzyna Kilis-PstrusinskaKatarzyna Kilis-Pstrusinska
Katarzyna Kilis-Pstrusinska
KAKatarzyna Akutko
Katarzyna Akutko
JBJoanna Barbara Braksator
Joanna Barbara Braksator
ADAnna Dancewicz
Anna Dancewicz
PGPatrycja Grosman-Dziewiszek
Patrycja Grosman-Dziewiszek
EJEwa Jankowska
Ewa Jankowska
The disease caused by coronavirus SARS-CoV-2 (COVID-19) can affect almost all organs of the human body, including kidneys. We conducted a one-center study to comprehensively analyze the effects of kidney involvement on the course and outcomes in patients hospitalized with COVID-19, depending on the estimated glomerular filtration rate (eGFR) at admission. Out of the 1958 patients, 1342 (68.54%) had eGFR ≥ 60 mL/min/1.73 m2 (group A) and 616 (31.46%) had eGFR < 60 mL/min/1.73 m2 (group B). Group B was additionally divided into subgroups B1, B2, and B3 based on eGFR. We found that mortality rates during hospitalization, as well as after 90 and 180 days, were much higher in group B than group A. The highest mortality was observed in the B2 subgroup with eGFR of 15–29. The mortality of B patients was associated with comorbidities, respiratory dysfunction, immunological impairment, and more frequent development of AKI. AKI had a negative impact on patients’ survival, regardless of the initial renal function. At discharge, 7.4% of patients had serum creatinine levels 30% higher, or more, as compared to admission. The disease course and outcomes in COVID-19 patients are associated with baseline eGFR; however, AKI during hospitalization is a more significant predictor of poor prognosis regardless of the initial renal function.

14 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AKAnna Kofla-Dłubacz
Anna Kofla-Dłubacz
KAKatarzyna Akutko
Katarzyna Akutko
EKElżbieta Krzesiek
Elżbieta Krzesiek
TJTatiana Jamer
Tatiana Jamer
JBJoanna Barbara Braksator
Joanna Barbara Braksator
ASAndrzej Stawarski
Andrzej Stawarski
Selective interference with the functioning of the immune system consisting of the selective blockade of pro-inflammatory factors is a modern, promising, and developing strategy for the treatment of diseases resulting from dysregulation of the immune system, including inflammatory bowel disease. Inhibition of the TNF alpha pathway, group 12/23 cytokines, and lymphocyte migration is used in the treatment of severe or moderate ulcerative colitis and Crohn’s disease. Intracellular signal transduction by influencing the phosphorylation of SAT (signal transducer and activator of transcription) proteins remains in clinical trials.

11 May 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
JBJoanna Barbara Braksator
Joanna Barbara Braksator
AKAnna Katarzyna Kofla-Dlubacz
Anna Katarzyna Kofla-Dlubacz
KAKatarzyna Antosz
Katarzyna Antosz
HSHubert Paweł Szyller
Hubert Paweł Szyller
JKJoanna Koga-Batko
Joanna Koga-Batko
TPTomasz Pytrus
Tomasz Pytrus
Helicobacter pylori and Candida spp. are widespread microorganisms found in the human gastrointestinal tract, often coexisting in the same ecological niche. H. pylori, a Gram-negative bacterium, is a well-known pathogen responsible for gastritis, peptic ulcers, and gastric cancer. In contrast, Candida fungi, often detected in food, particularly Candida albicans, are generally considered commensal organisms, but can become opportunistic pathogens under certain conditions. Recent studies suggest a possible link between these microorganisms, highlighting a new survival strategy of H. pylori, that is, its ability to internalize in Candida vacuoles. This phenomenon, confirmed by various microscopic and molecular techniques, may provide H. pylori with protection against adverse environmental conditions, especially clinically important antibiotic therapy. The basic premise of this theory is the ability of H. pylori to penetrate vacuoles in fungal cells, which then become a reservoir of infection, allowing the infection to recur. Understanding the interaction between H. pylori and Candida may offer new insights into the pathogenesis of gastrointestinal diseases and may lead to the development of treatments targeting both organisms simultaneously. The purpose of this article is to review the literature, considering the first observations on this problem in the literature and the current state of knowledge, and to suggest a direction for further research.